NASDAQ$MREO
Mereo Biopha-Adr · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Mereo Biopha-Adr Q1 fiscal 2026: $6.7M net loss, $0.01 loss per share
for the year ended December 31, 2025, filed with the SEC on March 19, 2026 (the “2025 Annual Report”). (SEC accession 0001193125-26-218232)
- Net loss: $6.7M
- Diluted EPS: $-0.01
- Operating income: $-8.8M
Headline financials
Revenue & EPS history
Mereo Biopha-Adr · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2026
+3.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+17.3%
Avg return
30 days after
69%
9 / 13 earnings
Positive
+11.9%
Q4 2023
Best reaction
-6.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | +0.9% | — | |
| Q4 2025 | +4.6% | -4.5% | -4.3% | |
| Q3 2025 | +6.3% | +0.6% | +27.1% | |
| Q2 2025 | +9.4% | +14.5% | +19.7% | |
| Q1 2025 | +1.3% | -2.2% | +25.3% | |
| Q4 2024 | -3.6% | -11.6% | +15.6% | |
| Q3 2023 | -5.4% | -17.5% | -12.9% | |
| Q3 2024 | -5.4% | -17.5% | -12.9% | |
| Q2 2024 | +6.2% | +16.4% | +18.0% | |
| Q1 2023 | +10.5% | +10.1% | +43.6% | |
| Q1 2024 | +10.5% | +10.1% | +43.6% | |
| Q4 2023 | +11.9% | +15.6% | -7.1% | |
| Q4 2022 | -6.1% | -10.3% | +52.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro